TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00248339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon-alpha-2b (PEG-Intron)
Description: PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon-alpha-2b (PEG-Intron)
Description: PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin-alpha (Procrit)
Description: PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin-alpha (Procrit)
Description: PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
Study: NCT01110980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallow therapy in combination with individual dietary counselling
Description: Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual dietary counselling
Description: Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
Study: NCT02788123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bismuth tripotassium dicitrate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: oral
Study: NCT03919955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine 80 mg, per mouth, before bed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin 5 mg, per mouth, before bed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, per mouth, before bed
Study: NCT00647608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride Extended-Release Capsules 160 mg
Description: 160mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inderal® LA Capsules 160 mg
Description: 160mg, single dose fed
Study: NCT03723291

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months
Description: • Arm B: A combination of pentoxifylline 800 mg/d in two 400-mg tablets and 1,000 IU/d of tocopherol acetate in two 500-IU aliquots in addition to best standard care \[a structured programme of rehabilitation exercises\] for 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: • Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months
Description: Prophylactic swallowing exercises consist of strap muscle exercises, airway protection exercises and base of tongue exercises
Study: NCT01573923

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mesenchymal stem cells
Description: Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy without cell therapy
Study: NCT02610049

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing therapy
Description: 8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson \& Chard (11/2010)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art + CPT
Description: 8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson \& Chard (11/2010)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPT + Art Therapy
Description: Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson \& Chard (1/2010) CPT + Art Therapy of mixed individual techniques
Study: NCT00711906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: Cotrimoxazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: Cotrimoxazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Description: Sulfadoxine-pyrimethamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Description: Sulfadoxine-pyrimethamine
Study: NCT02922114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
Study: NCT01486706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate
Description: 5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drugs
Description: will titrate medications similar to the active drug group
Study: NCT02684695

Intervention type: OTHER
Intervention: MRI scan (adolescent spine protocol)
Description: MRI scan of the lumbar spine and sacroiliac joints

Intervention type: OTHER
Intervention: MRI scan (whole body protocol)
Description: MRI scan of multiple joints ('whole body')
Study: NCT01858714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Therapy for Weight Loss
Description: Standard behavioral treatment for weight loss and weight loss maintenance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy + Environment
Description: Standard behavioral therapy with an emphasis on environmental strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavior Therapy + Environment
Description: Behavioral therapy with acceptance-based and environmental strategies.
Study: NCT04580056

Intervention type: PROCEDURE
Intervention: Uterine fundus endometrial incision during hysteroscopy
Description: Uterine fundus endometrial scratching during hysteroscopy by incision
Study: NCT01467063

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a PLACEBO drink. Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
Study: NCT03035279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-006
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-006
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-006
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous
Study: NCT01482819

Intervention type: DEVICE
Group type: OTHER
Intervention: polymacon
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: polymacon
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer

Intervention type: OTHER
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles owned by subject, non-specific manufacturer
Study: NCT02332434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope enrichment methodology (5,5,5-D3-L-Leucine)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope enrichment methodology (5,5,5-D3-L-Leucine)
Study: NCT00984347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas \[6th delivery and up\] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast pump nipple stimulation
Description: breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
Study: NCT02825849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of platelet rich plasma
Description: Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
Study: NCT00928876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret)
Description: anakinra 150 mg s/c. daily for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo s/c daily for four weeks
Study: NCT03238599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer-based activity monitoring after ASCT
Description: Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
Study: NCT05432258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulk-fill composite resin
Description: Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nano-fill composite resin
Description: Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
Study: NCT02363933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
Study: NCT03752229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Low Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study: NCT02702752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DYNASDY
Description: Measurement of SDF-1 alpha levels i patients' blood samples.
Study: NCT00797186

Intervention type: OTHER
Group type: OTHER
Intervention: Intensive risk factor management
Description: Aggressive medical and lifestyle therapy.
Study: NCT00145496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 5-10 mg sublingually twice daily for up to 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 5-20 mg by mouth once daily for up to 26 weeks
Study: NCT03002233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-820
Study: NCT02750371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of autobiographical memory
Description: Patients will answer several questionnaires one and two years after irradiation treatment end.
Study: NCT01579461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study: NCT00998114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise for 30-45 minutes five times a week for six months
Study: NCT05119166

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin B3
Description: ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.

Intervention type: BIOLOGICAL
Intervention: Azithromycin
Description: ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.

Intervention type: BIOLOGICAL
Intervention: Azithromycin
Description: ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fortified food supplement
Description: VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label).

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fortified food supplement
Description: VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label).
Study: NCT03597997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane
Description: Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
Study: NCT02166788

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inguinal Lymphadenectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ilio-inguinal Lymphadenectomy
Study: NCT03157414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
Study: NCT04205500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific carbohydrate diet
Description: Specific carbohydrate diet (see arm description)
Study: NCT02011633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR 500mg
Description: Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10mg
Description: Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Study: NCT03752229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ergoLance High Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance (light blue)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study: NCT02702752

Intervention type: OTHER
Group type: OTHER
Intervention: DYNASDY
Description: Measurement of SDF-1 alpha levels i patients' blood samples.
Study: NCT03680378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime 2 gram
Description: Combination of cefepime 2 gram with AAI101 1 gram
Study: NCT03752229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance (blue)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.